Cg Oncology, Inc. (CGON) — SEC Filings
Cg Oncology, Inc. (CGON) — 41 SEC filings. Latest: 4 (Apr 16, 2026). Includes 15 8-K, 8 SC 13G, 6 10-Q.
View Cg Oncology, Inc. on SEC EDGAR
Overview
Cg Oncology, Inc. (CGON) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 4 filed on Apr 16, 2026: On April 16, 2026, CG Oncology, Inc. filed a Form 4, reporting changes in beneficial ownership of securities. The filing details transactions by James M. Detore, a reporting person associated with the company. Specific details of the transactions, including the number of shares and dollar amounts, a
Sentiment Summary
Across 41 filings, the sentiment breakdown is: 5 bullish, 2 bearish, 34 neutral. The dominant filing sentiment for Cg Oncology, Inc. is neutral.
Filing Type Overview
Cg Oncology, Inc. (CGON) has filed 2 4, 15 8-K, 6 10-Q, 1 DEF 14A, 2 10-K, 3 S-1/A, 3 SC 13G/A, 8 SC 13G, 1 S-1 with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (41)
Risk Profile
Risk Assessment: Of CGON's 28 recent filings, 2 were flagged as high-risk, 10 as medium-risk, and 16 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $1.7M |
| Net Income | -$119.7M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $45.1M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- James M. Detore
- 0001623981
- Andrew "Andy" Lee
- Arthur Kuan
- CHEN YU
- Xiangmin Cui
Industry Context
The oncology drug development sector is characterized by intense competition, high R&D costs, and lengthy regulatory approval processes. Companies like CG Oncology are focused on developing novel therapies for unmet medical needs, often targeting specific cancer types or genetic mutations. Success hinges on robust clinical trial data, efficient manufacturing, and strategic partnerships to navigate the complex market landscape.
Top Tags
CG Oncology (5) · corporate-governance (4) · Biotechnology (4) · 10-Q (4) · biotech (4) · institutional-ownership (4) · R&D Expenses (3) · SEC Filing (3) · insider-buy (3) · IPO (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $119.7M | for the nine months ended September 30, 2025, up from $56.2 million in 2024 |
| Cash and Cash Equivalents | $45.1M | as of September 30, 2025, down from $257.1 million at December 31, 2024 |
| Marketable Securities | $635.1M | as of September 30, 2025, up from $484.9 million at December 31, 2024 |
| Total Revenues | $1.7M | for the nine months ended September 30, 2025, up from $0.7 million in 2024 |
| Research and Development Expenses | $86.7M | for the nine months ended September 30, 2025, up from $55.3 million in 2024 |
| General and Administrative Expenses | $55.5M | for the nine months ended September 30, 2025, up from $22.0 million in 2024 |
| Accumulated Deficit | $337.7M | as of September 30, 2025 |
| Net Proceeds from Public Offering | $48.7M | from the sale of 1,515,151 shares at $33.00 per share during Q3 2025 |
| Commission File Number | 001-41925 | Identifies the company's SEC filing history. |
| IRS Employer Identification No. | 37-1611499 | Tax identification number for the company. |
| Reporting Period End Date | 2025-03-31 | Indicates the end of the financial quarter being reported. |
| Employee Stock Purchase Plan Start Date | 2024-01-11 | Marks the commencement of the company's employee stock purchase plan. |
| Underwriters Agreement Date | 2024-01-29 | Specifies the date related to agreements with underwriters. |
| SIC Code | 2836 | Biological Products (No Diagnostic Substances) |
| IRS Number | 37-1611499 | Employer Identification Number |
Forward-Looking Statements
- {"claim":"CG Oncology, Inc. stock may experience increased investor interest due to the significant institutional stake.","entity":"CG Oncology, Inc.","targetDate":"Q2 2024","confidence":"medium"}
- {"claim":"CG Oncology's stock price will see increased investor confidence due to this significant institutional investment.","entity":"CG Oncology, Inc.","targetDate":"Q2 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Cg Oncology, Inc. (CGON)?
Cg Oncology, Inc. has 41 recent SEC filings from Jan 2024 to Apr 2026, including 15 8-K, 8 SC 13G, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CGON filings?
Across 41 filings, the sentiment breakdown is: 5 bullish, 2 bearish, 34 neutral. The dominant sentiment is neutral.
Where can I find Cg Oncology, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Cg Oncology, Inc. (CGON) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Cg Oncology, Inc.?
Key financial highlights from Cg Oncology, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CGON?
The investment thesis for CGON includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Cg Oncology, Inc.?
Key executives identified across Cg Oncology, Inc.'s filings include James M. Detore, 0001623981, Andrew "Andy" Lee, Arthur Kuan, CHEN YU and 1 others.
What are the main risk factors for Cg Oncology, Inc. stock?
Of CGON's 28 assessed filings, 2 were flagged high-risk, 10 medium-risk, and 16 low-risk.
What are recent predictions and forward guidance from Cg Oncology, Inc.?
Recent forward-looking statements from Cg Oncology, Inc. include guidance on {"claim":"CG Oncology, Inc. stock may experience increased investor interest due to the significant institutional stake. and 1 other predictions.